N

NextCure
D

NXTC

1.32000
USD
0.03
(2.33%)
مغلق
حجم التداول
366
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
36,928,109
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ACN
    -2.48
    (-0.75%)
    328.07 USD
    D
    DXC
    -0.480
    (-2.36%)
    19.880 USD
    E
    EPAM
    -0.340
    (-0.16%)
    214.810 USD
    F
    FIS
    -1.780
    (-2.32%)
    75.070 USD
    F
    FISV
    0
    (0%)
    0.000000 USD
    G
    GIB
    -2.590
    (-2.27%)
    111.510 USD
    L
    LDOS
    0.320
    (0.22%)
    144.770 USD
    N
    NCR
    0.860
    (3.28%)
    27.090 USD
    S
    SAIC
    -1.060
    (-0.85%)
    123.320 USD
    S
    SY
    -0.07040
    (-7.25%)
    0.90110 USD
    المزيد
الأخبار
المقالات

العنوان: NextCure

القطاع: Healthcare
الصناعة: Biotechnology
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.